Health Care & Life Sciences » Biotechnology | Mount TAM Biotechnologies Inc.

Mount TAM Biotechnologies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
17.60
-
-
-
-
1,816.70
Cost of Goods Sold (COGS) incl. D&A
17.50
-
-
-
-
-
Gross Income
0.00
-
-
-
-
-
SG&A Expense
174.70
98.80
2,087.30
2,078.80
2,530.80
1,816.70
EBIT
174.70
98.80
2,087.30
2,078.80
2,530.80
1,816.70
Non Operating Income/Expense
-
-
-
-
0.50
332.80
Interest Expense
-
-
8.10
101.80
85.80
343.90
Pretax Income
174.70
98.80
2,095.30
2,180.60
2,616.10
1,827.80
Consolidated Net Income
174.70
98.80
2,095.30
2,180.60
2,616.10
1,827.80
Net Income
174.70
98.80
2,095.30
2,180.60
2,616.10
1,827.80
Net Income After Extraordinaries
174.70
98.80
2,095.30
2,180.60
2,616.10
1,827.80
Net Income Available to Common
174.70
98.80
2,095.30
2,180.60
2,616.10
1,827.80
EPS (Basic)
0.00
0.00
0.07
0.05
0.05
0.03
Basic Shares Outstanding
41,244.20
44,533.80
31,286.90
44,492.60
50,273.90
54,495.30
EPS (Diluted)
0.00
0.00
0.07
0.05
0.05
0.03
Diluted Shares Outstanding
41,244.20
44,533.80
31,286.90
44,492.60
50,273.90
54,495.30
EBITDA
174.70
98.80
2,087.30
2,078.80
2,530.80
1,816.70

About Mount TAM Biotechnologies

View Profile
Address
106 Main Street
Burlington Vermont 05401
United States
Employees -
Website http://www.mounttambiotech.com
Updated 07/08/2019
Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.